✦ LIBER ✦

Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)

✍ Scribed by A Nicolini; PA Mancini; P Ferrari; L Anselmi; G Tartarelli; V Bonazzi; A Carpi; R Giardino

Book ID: 116313481
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 128 KB
Volume: 58
Category: Article
ISSN: 0753-3322
DOI: 10.1016/j.biopha.2004.08.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel, low-dose estramustine, and do

Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer

✍ Yoshihiro Wada; Ken Kikuchi; Wataru Takahashi; Jiro Honda; Juro Nakanishi; Koich 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 409 KB

Oral Cyclophosphamide for the Management

Oral Cyclophosphamide for the Management of Hormone-refractory Prostate Cancer

✍ D. RAGHAVAN; K. COX; B. S. PEARSON; G. J. COOREY; J. ROGERS; W. HUNTER WATT; A. 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB

Treatment of Metastatic Hormone Refracto

Treatment of Metastatic Hormone Refractory Prostate Cancer with Ketoconazole, Hydrocortisone, and Cyclophosphamide

✍ Andrew Pecora; Frank Richter; Anna Pavlick; Vincent Lanteri; John Scheuch; Stuar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Low doses of oral dexamethasone for horm

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

✍ Kazuo Nishimura; Norio Nonomura; Yutaka Yasunaga; Natsuki Takaha; Hitoshi Inoue; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Treatment in metastatic prostate cancer

Treatment in metastatic prostate cancer with hormone refractory

✍ S. Vitello; F. Vacirca; E. Triglia; G. Giarratano 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 33 KB

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi